리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2025년 07월
페이지 정보:영문 385 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 종합 대사 패널 검사 시장은 2030년까지 181억 달러에 도달
2024년에 115억 달러로 추정되는 세계의 종합 대사 패널 검사 시장은 2024-2030년에 CAGR 7.8%로 성장하며, 2030년에는 181억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 글루코오스는 CAGR 9.7%를 기록하며, 분석 기간 종료시에는 37억 달러에 달할 것으로 예측됩니다. 크레아티닌 부문의 성장률은 분석 기간에 CAGR 8.4%로 추정됩니다.
미국 시장은 31억 달러로 추정되는 한편, 중국은 CAGR 12.4%로 성장할 것으로 예측
미국의 종합 대사 패널 검사 시장은 2024년에 31억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 39억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 12.4%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 3.8%와 7.6%로 예측됩니다. 유럽에서는 독일이 CAGR 5.2%로 성장할 것으로 예측됩니다.
세계의 종합 대사 패널 검사 시장 - 주요 동향과 촉진요인 정리
종합대사패널 검사의 중요성이 높아지는 이유는 무엇인가?
종합 대사 패널 검사는 전반적인 대사 기능, 장기 건강 상태, 전해질 균형에 대한 귀중한 인사이트를 제공하는 현대 헬스케어의 중요한 툴이 되었습니다. 포도당 수치, 신장 기능, 간 효소, 전해질 불균형을 측정하는 이 혈액 검사는 일상적인 건강 검진, 만성질환 관리, 수술 전 평가에 널리 사용되고 있습니다. 대사이상, 신장질환, 간 질환의 유병률이 증가함에 따라 병원, 진단 실험실, 외래 진료소 전체에서 CMP 검사에 대한 수요가 꾸준히 증가하고 있습니다. 당뇨병과 심혈관계 질환의 세계적 부담 증가는 CMP 검사 도입의 주요 원동력이 되고 있습니다. 대사이상을 조기에 발견하면 의료진은 당뇨병, 고혈압, 신장 기능 장애와 같은 병이 심각한 합병증으로 발전하기 전에 진단하고 관리할 수 있습니다. 또한 노인 인구가 증가함에 따라 정기적인 대사 평가의 필요성이 높아지고 있습니다. 노인은 지속적인 모니터링이 필요한 여러 만성질환의 위험이 높기 때문입니다. CMP 검사에 대한 수요를 촉진하는 또 다른 중요한 요인은 전 세계에서 예방 의료 구상이 확대되고 있다는 점입니다. 정부와 의료기관은 비감염성 질환의 발생률을 낮추기 위해 정기적인 건강검진을 적극 장려하고 있습니다. 기업 웰니스 프로그램 및 건강 보험 프로바이더들도 정기적인 혈액 검사를 장려하고 있으며, 이는 CMP 검사량 증가로 이어지고 있습니다. 헬스케어 시스템이 반응적 접근 방식에서 예방적 접근 방식으로 전환하는 가운데, 종합적인 대사 패널은 환자의 적극적인 치료에 중요한 역할을 하고 있습니다.
기술의 발전은 CMP 검사의 정확성과 효율성을 어떻게 향상시키고 있는가?
진단 기술의 발전으로 종합 대사 패널 검사의 정확도, 속도, 접근성이 크게 향상되고 있습니다. 생화학 자동 분석기의 도입은 임상 실험실에 혁명을 가져왔으며, 최소한의 인력 개입으로 보다 빠르고 정확한 검사를 가능하게 했습니다. 이러한 발전으로 소요 시간이 단축되어 신속한 진단과 치료 방침을 결정할 수 있게 되었습니다. 또한 시약 처방과 분석의 표준화가 개선되어 대사 패널 결과의 신뢰성이 향상되고 진단 정확도가 더욱 확실해졌습니다. 현장진단검사(POCT) 또한 CMP 검사 상황을 바꿀 수 있는 큰 기술 개발입니다. 휴대용 휴대용 생화학 분석기를 통해 응급실, 외래 진료소, 심지어 재택 환경에서도 즉석에서 대사 평가를 할 수 있게 되었습니다. 기존의 검사 인프라 없이도 빠른 결과를 얻을 수 있게 되어 환자의 편의성이 향상되고 임상 워크플로우가 간소화되었습니다. 진단실험실에서 인공지능(AI)과 머신러닝의 통합은 CMP 검사의 효율성을 더욱 최적화하고 있습니다. AI 기반 데이터 분석 플랫폼은 동향 파악, 이상 결과 플래그 지정, 대사 건강 상태에 대한 예측적 인사이트 제공에 활용되고 있습니다. 이러한 기술은 의사의 질병 조기 발견과 위험 평가를 돕고 환자의 예후를 개선하는 데 도움을 주고 있습니다. 또한 전자의무기록(EHR)을 통한 검사 결과의 디지털화는 데이터에 대한 접근성을 높이고, 환자와 의료진의 대사 상태 관리에 있으며, 더 나은 협업을 가능하게 하고 있습니다.
CMP 검사의 성장을 가속하는 시장 동향은?
종합 대사 패널 검사 시장을 형성하는 가장 주목할 만한 동향 중 하나는 재택 진단 솔루션의 채택이 증가하고 있다는 점입니다. 소비자 직접 판매(DTC) 검사 서비스의 등장으로 개인은 의사의 의뢰 없이도 CMP 검사를 주문하여 자신의 건강을 관리할 수 있게 되었습니다. 온라인 건강 플랫폼과 원격의료 서비스 프로바이더는 재택 채혈 키트를 제공하고 있으며, 사용자는 실험실 분석을 위해 샘플을 제출하고 디지털 결과를 받을 수 있습니다. 이러한 추세는 편리함과 예방적 건강관리를 우선시하는 기술에 정통한 소비자들 사이에서 특히 지지를 받고 있습니다. 진단 실험실 네트워크와 전략적 파트너십의 확대도 시장 성장을 가속하고 있습니다. 주요 진단 서비스 프로바이더들은 새로운 검사 시설을 개설하거나 병원 및 클리닉과 제휴를 맺는 등 그 영역을 넓혀가고 있습니다. 이러한 제휴를 통해 특히 의료 미개발 지역에서 CMP 검사에 대한 폭넓은 접근성이 확보되고 있으며, 특히 고급 진단 서비스가 제한적이었던 의료 미개발 지역에서 CMP 검사에 대한 접근성이 높아지고 있습니다. 또한 다국적 진단 기업은 신흥 시장에서의 대사성 검진에 대한 수요 증가를 인식하고 신흥 시장에 투자하고 있습니다. 검사 시설의 품질 기준과 검사 상환 정책을 개선하기 위한 규제 당국의 노력은 시장 역학을 더욱 형성하고 있습니다. 많은 국가에서 생화학 검사의 정확성과 신뢰성을 보장하기 위해 엄격한 가이드라인을 도입하여 진단 서비스에 대한 신뢰를 형성하고 있습니다. 동시에 CMP를 포함한 일상적인 혈액 검사에 대한 의료 보험 적용 범위가 일부 지역에서 개선되고 있으며, 이러한 검사는 더 저렴한 가격으로 더 많은 환자 집단이 이용할 수 있습니다. 의료 지불자가 질병의 조기 발견을 통한 비용 절감 효과를 인식함에 따라 예방적 대사 검진에 대한 보험 적용 정책이 확대될 것으로 예측됩니다.
시장을 촉진하는 주요 성장 요인은 무엇인가?
종합 대사 패널 검사 시장의 성장은 진단 자동화의 발전, 만성질환 유병률 증가, POC(Point-Of-Care) 검사 솔루션의 확대 등 여러 가지 요인에 의해 이루어지고 있습니다. 주요 성장 요인 중 하나는 대사성 질환, 특히 당뇨병, 비만, 신장질환의 유병률 상승입니다. 이러한 질환이 확산됨에 따라 정기적인 대사 평가가 질환의 모니터링과 관리에 필수적이어서 검사량이 증가하고 있습니다. 디지털 헬스 솔루션의 채택이 증가하고 있는 것도 시장 확대에 기여하는 주요 요인입니다. 원격의료 플랫폼은 CMP 검사를 가상 진료 모델에 통합하여 원격 환자 모니터링을 가능하게 하고, 만성질환 관리를 강화합니다. 디지털 헬스 기업은 검사 시설과 제휴하여 원활한 온라인 검사 주문 및 결과 전달을 제공함으로써 대사 패널 검사를 보다 편리하고 쉽게 이용할 수 있도록 하고 있습니다. 진단학과 디지털 건강의 융합으로 임상과 재택 환경 모두에서 CMP 검사가 지속적으로 보급될 것으로 예측됩니다. 신흥 국가의 헬스케어 인프라 확충도 시장 성장에 중요한 역할을 하고 있습니다. 신흥 국가에서는 진단 실험실과 병원 시설에 대한 투자가 증가하고 정기적인 건강검진에 대한 접근성이 향상되고 있습니다. 이들 지역의 정부는 질병의 조기 발견을 촉진하기 위해 공중 보건 구상을 내놓고 있으며, CMP 검사에 대한 수요를 더욱 증가시키고 있습니다. 또한 신흥 시장의 가처분 소득 증가와 건강 인식 증가는 예방적 헬스케어 서비스를 찾는 개인들의 행동을 촉진하여 전체 시장 확대에 기여하고 있습니다. 또한 대사 패널 검사에서 바이오마커 검출 강화를 위한 연구개발이 진행되고 있으며, 새로운 성장 기회 개발이 기대되고 있습니다. 과학자들은 신진대사 건강 상태에 대한 더 깊은 인사이트를 제공하고 보다 정확한 위험 평가와 개인화된 치료 계획을 가능하게 하는 새로운 바이오마커를 탐색하고 있습니다. 진단 기능이 계속 진화하는 가운데, 종합대사 패널 검사 시장은 기술 혁신, 의료 접근성 확대, 예방 의학의 중요성 증가에 힘입어 지속적인 성장이 예상됩니다.
부문
분석 항목(글루코오스, 크레아티닌, Ca++, ALT, BUN, K+, 총단백질, 총빌리루빈, 기타 분석 항목); 질환(신장병, 당뇨병, 간질환, 기타 질환); 최종 사용(검사실최종 사용, PoC 최종 사용)
조사 대상 기업의 예
Abbott Laboratories
American Esoteric Laboratories
ARUP Laboratories
Baptist Health Medical Group
CENTOGENE N.V.
Charles River Laboratories Inc.
Genoptix Inc.
LabCorp Drug Development
Laboratory Corporation of America Holdings(LabCorp)
Laboratory Services of America
NeoGenomics Laboratories, Inc.
Nova Medical
Quest Diagnostics
Scion Lab Services LLC
Siemens Healthcare GmbH
Sonic Healthcare
SYNLAB International GmbH
TCG Corp.
UNIPATH
Walk-In Lab, LLC
AI 통합
당사는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.
Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.
관세 영향 계수
Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.
목차
제1장 조사 방법
제2장 개요
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
스페인
러시아
기타 유럽
아시아태평양
호주
인도
한국
기타 아시아태평양
라틴아메리카
아르헨티나
브라질
멕시코
기타 라틴아메리카
중동
이란
이스라엘
사우디아라비아
아랍에미리트
기타 중동
아프리카
제4장 경쟁
KSA
영문 목차
영문목차
Global Comprehensive Metabolic Panel Testing Market to Reach US$18.1 Billion by 2030
The global market for Comprehensive Metabolic Panel Testing estimated at US$11.5 Billion in the year 2024, is expected to reach US$18.1 Billion by 2030, growing at a CAGR of 7.8% over the analysis period 2024-2030. Glucose, one of the segments analyzed in the report, is expected to record a 9.7% CAGR and reach US$3.7 Billion by the end of the analysis period. Growth in the Creatinine segment is estimated at 8.4% CAGR over the analysis period.
The U.S. Market is Estimated at US$3.1 Billion While China is Forecast to Grow at 12.4% CAGR
The Comprehensive Metabolic Panel Testing market in the U.S. is estimated at US$3.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.9 Billion by the year 2030 trailing a CAGR of 12.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.8% and 7.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.2% CAGR.
Why Is Comprehensive Metabolic Panel Testing Becoming Increasingly Important?
Comprehensive metabolic panel testing has become a critical tool in modern healthcare, providing valuable insights into overall metabolic function, organ health, and electrolyte balance. This blood test, which measures glucose levels, kidney function, liver enzymes, and electrolyte imbalances, is widely used for routine health check-ups, chronic disease management, and preoperative assessments. With the rising prevalence of metabolic disorders, kidney diseases, and liver conditions, the demand for CMP testing is steadily increasing across hospitals, diagnostic laboratories, and outpatient clinics. The growing global burden of diabetes and cardiovascular diseases has been a major driver for CMP testing adoption. Early detection of metabolic abnormalities allows healthcare providers to diagnose and manage conditions such as diabetes mellitus, hypertension, and kidney dysfunction before they progress into severe complications. Additionally, with the increasing geriatric population, the need for regular metabolic assessments has risen, as older individuals are at higher risk for multiple chronic conditions that require continuous monitoring. Another significant factor driving CMP testing demand is the expansion of preventive healthcare initiatives worldwide. Governments and healthcare organizations are actively promoting regular health screenings to reduce the incidence of non-communicable diseases. Corporate wellness programs and health insurance providers are also incentivizing routine blood tests, leading to an increase in CMP testing volumes. As healthcare systems shift from reactive to preventive approaches, comprehensive metabolic panels are playing a crucial role in proactive patient care.
How Are Technological Advancements Enhancing the Accuracy and Efficiency of CMP Testing?
The evolution of diagnostic technologies has significantly improved the accuracy, speed, and accessibility of comprehensive metabolic panel testing. The introduction of automated biochemical analyzers has revolutionized clinical laboratories, enabling faster and more precise testing with minimal human intervention. These advancements have reduced turnaround times, allowing for quicker diagnosis and treatment decisions. Additionally, improvements in reagent formulations and assay standardization have enhanced the reliability of metabolic panel results, ensuring greater diagnostic accuracy. Point-of-care testing (POCT) is another major technological development that is transforming the CMP testing landscape. Portable and handheld biochemical analyzers now allow for on-the-spot metabolic assessments in emergency rooms, outpatient clinics, and even home settings. The ability to obtain rapid results without requiring traditional laboratory infrastructure has improved patient convenience and streamlined clinical workflows, particularly in critical care scenarios where timely intervention is crucial. The integration of artificial intelligence (AI) and machine learning in diagnostic laboratories is further optimizing CMP testing efficiency. AI-powered data analytics platforms are being used to identify trends, flag abnormal results, and provide predictive insights into metabolic health. These technologies are aiding physicians in early disease detection and risk assessment, improving patient outcomes. Moreover, the digitization of lab results through electronic health records (EHR) is enhancing data accessibility and enabling better patient-provider collaboration in managing metabolic conditions.
What Market Trends Are Driving the Growth of CMP Testing?
One of the most notable trends shaping the comprehensive metabolic panel testing market is the increasing adoption of at-home diagnostic solutions. The rise of direct-to-consumer (DTC) testing services has empowered individuals to take charge of their health by ordering CMP tests without the need for physician referrals. Online health platforms and telemedicine providers are offering home-based blood collection kits, allowing users to submit samples for laboratory analysis and receive digital results. This trend is particularly gaining traction among tech-savvy consumers who prioritize convenience and preventive healthcare. The expansion of diagnostic laboratory networks and strategic partnerships is also fueling market growth. Leading diagnostic service providers are expanding their footprints by opening new testing facilities and forming collaborations with hospitals and clinics. These partnerships are ensuring wider accessibility to CMP testing, particularly in underserved regions where advanced diagnostic services were previously limited. Additionally, multinational diagnostic companies are investing in emerging markets, recognizing the growing demand for metabolic screening in developing countries. Regulatory efforts to improve laboratory quality standards and test reimbursement policies are further shaping market dynamics. Many countries are implementing stringent guidelines to ensure the accuracy and reliability of biochemical testing, fostering trust in diagnostic services. At the same time, health insurance coverage for routine blood tests, including CMPs, is improving in several regions, making these tests more affordable and accessible to a larger patient population. As healthcare payers recognize the cost-saving benefits of early disease detection, coverage policies for preventive metabolic screening are expected to expand.
What Are the Key Growth Drivers Fueling the Market?
The growth in the comprehensive metabolic panel testing market is driven by several factors, including advancements in diagnostic automation, increasing chronic disease prevalence, and the expansion of point-of-care testing solutions. One of the primary growth drivers is the rising incidence of metabolic disorders, particularly diabetes, obesity, and kidney disease. As these conditions become more widespread, regular metabolic assessments are becoming essential for disease monitoring and management, leading to higher testing volumes. The increasing adoption of digital health solutions is another major factor contributing to market expansion. Telemedicine platforms are integrating CMP testing into virtual care models, enabling remote patient monitoring and enhancing chronic disease management. Digital health companies are partnering with laboratories to offer seamless online test ordering and result delivery, making metabolic panel testing more convenient and accessible. The convergence of diagnostics and digital health is expected to drive continued adoption of CMP testing in both clinical and home settings. The expansion of healthcare infrastructure in emerging economies is also playing a crucial role in market growth. Developing countries are witnessing increased investments in diagnostic laboratories and hospital facilities, improving access to routine health screenings. Governments in these regions are launching public health initiatives to promote early disease detection, further driving demand for CMP testing. Additionally, the rising disposable incomes and growing health consciousness in emerging markets are encouraging individuals to seek preventive healthcare services, contributing to the overall market expansion. Furthermore, ongoing research and development efforts aimed at enhancing biomarker detection in metabolic panel testing are expected to open new growth opportunities. Scientists are exploring novel biomarkers that can provide deeper insights into metabolic health, enabling more precise risk assessment and personalized treatment plans. As diagnostic capabilities continue to evolve, the comprehensive metabolic panel testing market is poised for sustained growth, driven by technological innovation, expanding healthcare access, and the increasing emphasis on preventive medicine.
SCOPE OF STUDY:
The report analyzes the Comprehensive Metabolic Panel Testing market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Analytes (Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin, Other Analytes); Disease (Kidney Diseases, Diabetes, Liver Diseases, Other Diseases); End-Use (Laboratories End-Use, PoC End-Use)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 34 Featured) -
Abbott Laboratories
American Esoteric Laboratories
ARUP Laboratories
Baptist Health Medical Group
CENTOGENE N.V.
Charles River Laboratories Inc.
Genoptix Inc.
LabCorp Drug Development
Laboratory Corporation of America Holdings (LabCorp)
Laboratory Services of America
NeoGenomics Laboratories, Inc.
Nova Medical
Quest Diagnostics
Scion Lab Services LLC
Siemens Healthcare GmbH
Sonic Healthcare
SYNLAB International GmbH
TCG Corp.
UNIPATH
Walk-In Lab, LLC
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
Tariff Impact on Global Supply Chain Patterns
Comprehensive Metabolic Panel Testing - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Focus on Preventive Healthcare and Routine Screening Drives Demand for Metabolic Panel Testing
Expansion of Wellness Programs and Annual Health Check-Ups Fuels Clinical Adoption
OEM Integration With Lab Information Systems and EHR Enhances Test Ordering and Reporting Efficiency
Growing Use in Chronic Disease Management Programs Supports Repeat and Panelized Testing
Increased Use in Preoperative Evaluations and Baseline Assessments Enhances Test Frequency
OEM Development of Automated and High-Throughput Analyzers Supports Laboratory Efficiency
Growing Role of Telemedicine and At-Home Sample Collection Expands Access to Testing
OEMs Offering Multiplexed Assays and Expanded Biomarker Panels Improve Diagnostic Value
Rising Utilization in Monitoring Liver, Kidney, and Electrolyte Function Across Age Groups Broadens Application
OEMs Supporting Customizable Panel Configurations Enable Use in Specialized Clinical Settings
Growth in Corporate Wellness and Occupational Health Screening Programs Drives Institutional Demand
OEM Collaborations With Diagnostic Labs and Clinics Expand Geographic and Segment Reach
Increased Insurance Coverage and Employer Reimbursement Models Encourage Test Utilization
OEMs Offering Integration With Decision Support Tools Improve Interpretation and Clinical Actionability
Rise in Point-of-Care Testing and Rapid Diagnostic Platforms Enhances Speed of Diagnosis
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Comprehensive Metabolic Panel Testing Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Comprehensive Metabolic Panel Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 4: World 15-Year Perspective for Comprehensive Metabolic Panel Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Glucose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for Glucose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 7: World 15-Year Perspective for Glucose by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Creatinine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for Creatinine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 10: World 15-Year Perspective for Creatinine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Ca++ by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for Ca++ by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 13: World 15-Year Perspective for Ca++ by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for ALT by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for ALT by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 16: World 15-Year Perspective for ALT by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for BUN by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for BUN by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 19: World 15-Year Perspective for BUN by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for K+ by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 21: World Historic Review for K+ by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 22: World 15-Year Perspective for K+ by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Total Protein by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 24: World Historic Review for Total Protein by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 25: World 15-Year Perspective for Total Protein by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Total Bilirubin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 27: World Historic Review for Total Bilirubin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 28: World 15-Year Perspective for Total Bilirubin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 29: World Recent Past, Current & Future Analysis for Other Analytes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 30: World Historic Review for Other Analytes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 31: World 15-Year Perspective for Other Analytes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 32: World Recent Past, Current & Future Analysis for Kidney Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 33: World Historic Review for Kidney Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 34: World 15-Year Perspective for Kidney Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 35: World Recent Past, Current & Future Analysis for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 36: World Historic Review for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 37: World 15-Year Perspective for Diabetes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 38: World Recent Past, Current & Future Analysis for Liver Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 39: World Historic Review for Liver Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 40: World 15-Year Perspective for Liver Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 41: World Recent Past, Current & Future Analysis for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 42: World Historic Review for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 43: World 15-Year Perspective for Other Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 44: World Recent Past, Current & Future Analysis for Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 45: World Historic Review for Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 46: World 15-Year Perspective for Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 47: World Recent Past, Current & Future Analysis for PoC End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 48: World Historic Review for PoC End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 49: World 15-Year Perspective for PoC End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Comprehensive Metabolic Panel Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 50: USA Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 51: USA Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 52: USA 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
TABLE 53: USA Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 54: USA Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 55: USA 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
TABLE 56: USA Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 57: USA Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 58: USA 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
CANADA
TABLE 59: Canada Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 60: Canada Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 61: Canada 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
TABLE 62: Canada Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 63: Canada Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 64: Canada 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
TABLE 65: Canada Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 66: Canada Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 67: Canada 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
JAPAN
Comprehensive Metabolic Panel Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 68: Japan Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 69: Japan Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 70: Japan 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
TABLE 71: Japan Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 72: Japan Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 73: Japan 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
TABLE 74: Japan Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 75: Japan Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 76: Japan 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
CHINA
Comprehensive Metabolic Panel Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 77: China Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 78: China Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 79: China 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
TABLE 80: China Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 81: China Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 82: China 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
TABLE 83: China Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 84: China Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 85: China 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
EUROPE
Comprehensive Metabolic Panel Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 86: Europe Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 87: Europe Historic Review for Comprehensive Metabolic Panel Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 88: Europe 15-Year Perspective for Comprehensive Metabolic Panel Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
TABLE 89: Europe Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 90: Europe Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 91: Europe 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
TABLE 92: Europe Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 93: Europe Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 94: Europe 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
TABLE 95: Europe Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 96: Europe Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 97: Europe 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
FRANCE
Comprehensive Metabolic Panel Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 98: France Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 99: France Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 100: France 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
TABLE 101: France Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 102: France Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 103: France 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
TABLE 104: France Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 105: France Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 106: France 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
GERMANY
Comprehensive Metabolic Panel Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 107: Germany Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 108: Germany Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 109: Germany 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
TABLE 110: Germany Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 111: Germany Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 112: Germany 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
TABLE 113: Germany Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 114: Germany Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 115: Germany 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
ITALY
TABLE 116: Italy Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 117: Italy Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 118: Italy 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
TABLE 119: Italy Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 120: Italy Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 121: Italy 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
TABLE 122: Italy Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 123: Italy Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 124: Italy 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
UNITED KINGDOM
Comprehensive Metabolic Panel Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 125: UK Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 126: UK Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 127: UK 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
TABLE 128: UK Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 129: UK Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 130: UK 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
TABLE 131: UK Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 132: UK Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 133: UK 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
SPAIN
TABLE 134: Spain Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 135: Spain Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 136: Spain 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
TABLE 137: Spain Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 138: Spain Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 139: Spain 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
TABLE 140: Spain Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 141: Spain Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 142: Spain 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
RUSSIA
TABLE 143: Russia Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 144: Russia Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 145: Russia 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
TABLE 146: Russia Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 147: Russia Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 148: Russia 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
TABLE 149: Russia Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 150: Russia Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 151: Russia 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
REST OF EUROPE
TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 153: Rest of Europe Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 154: Rest of Europe 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
TABLE 155: Rest of Europe Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 156: Rest of Europe Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 157: Rest of Europe 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
TABLE 158: Rest of Europe Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 159: Rest of Europe Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 160: Rest of Europe 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
ASIA-PACIFIC
Comprehensive Metabolic Panel Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 162: Asia-Pacific Historic Review for Comprehensive Metabolic Panel Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 163: Asia-Pacific 15-Year Perspective for Comprehensive Metabolic Panel Testing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 165: Asia-Pacific Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 166: Asia-Pacific 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 168: Asia-Pacific Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 169: Asia-Pacific 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
TABLE 170: Asia-Pacific Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 171: Asia-Pacific Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 172: Asia-Pacific 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
AUSTRALIA
Comprehensive Metabolic Panel Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
TABLE 173: Australia Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 174: Australia Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 175: Australia 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
TABLE 176: Australia Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 177: Australia Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 178: Australia 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
TABLE 179: Australia Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 180: Australia Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 181: Australia 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
INDIA
Comprehensive Metabolic Panel Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
TABLE 182: India Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 183: India Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 184: India 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
TABLE 185: India Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 186: India Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 187: India 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
TABLE 188: India Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 189: India Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 190: India 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
SOUTH KOREA
TABLE 191: South Korea Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 192: South Korea Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 193: South Korea 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
TABLE 194: South Korea Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 195: South Korea Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 196: South Korea 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
TABLE 197: South Korea Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 198: South Korea Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 199: South Korea 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
REST OF ASIA-PACIFIC
TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 201: Rest of Asia-Pacific Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 202: Rest of Asia-Pacific 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
TABLE 203: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 204: Rest of Asia-Pacific Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 205: Rest of Asia-Pacific 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
TABLE 206: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 207: Rest of Asia-Pacific Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 208: Rest of Asia-Pacific 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
LATIN AMERICA
Comprehensive Metabolic Panel Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
TABLE 209: Latin America Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 210: Latin America Historic Review for Comprehensive Metabolic Panel Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 211: Latin America 15-Year Perspective for Comprehensive Metabolic Panel Testing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
TABLE 212: Latin America Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 213: Latin America Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 214: Latin America 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
TABLE 215: Latin America Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 216: Latin America Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 217: Latin America 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
TABLE 218: Latin America Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 219: Latin America Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 220: Latin America 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
ARGENTINA
TABLE 221: Argentina Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 222: Argentina Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 223: Argentina 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
TABLE 224: Argentina Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 225: Argentina Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 226: Argentina 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
TABLE 227: Argentina Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 228: Argentina Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 229: Argentina 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
BRAZIL
TABLE 230: Brazil Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 231: Brazil Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 232: Brazil 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
TABLE 233: Brazil Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 234: Brazil Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 235: Brazil 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
TABLE 236: Brazil Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 237: Brazil Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 238: Brazil 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
MEXICO
TABLE 239: Mexico Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 240: Mexico Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 241: Mexico 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
TABLE 242: Mexico Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 243: Mexico Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 244: Mexico 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
TABLE 245: Mexico Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 246: Mexico Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 247: Mexico 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
REST OF LATIN AMERICA
TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 249: Rest of Latin America Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 250: Rest of Latin America 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
TABLE 251: Rest of Latin America Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 252: Rest of Latin America Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 253: Rest of Latin America 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
TABLE 254: Rest of Latin America Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 255: Rest of Latin America Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 256: Rest of Latin America 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
MIDDLE EAST
Comprehensive Metabolic Panel Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
TABLE 257: Middle East Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 258: Middle East Historic Review for Comprehensive Metabolic Panel Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 259: Middle East 15-Year Perspective for Comprehensive Metabolic Panel Testing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
TABLE 260: Middle East Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 261: Middle East Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 262: Middle East 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
TABLE 263: Middle East Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 264: Middle East Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 265: Middle East 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
TABLE 266: Middle East Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 267: Middle East Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 268: Middle East 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
IRAN
TABLE 269: Iran Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 270: Iran Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 271: Iran 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
TABLE 272: Iran Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 273: Iran Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 274: Iran 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
TABLE 275: Iran Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 276: Iran Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 277: Iran 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
ISRAEL
TABLE 278: Israel Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 279: Israel Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 280: Israel 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
TABLE 281: Israel Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 282: Israel Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 283: Israel 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
TABLE 284: Israel Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 285: Israel Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 286: Israel 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
SAUDI ARABIA
TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 288: Saudi Arabia Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 289: Saudi Arabia 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
TABLE 290: Saudi Arabia Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 291: Saudi Arabia Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 292: Saudi Arabia 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
TABLE 293: Saudi Arabia Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 294: Saudi Arabia Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 295: Saudi Arabia 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
UNITED ARAB EMIRATES
TABLE 296: UAE Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 297: UAE Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 298: UAE 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
TABLE 299: UAE Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 300: UAE Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 301: UAE 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
TABLE 302: UAE Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 303: UAE Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 304: UAE 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
REST OF MIDDLE EAST
TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 306: Rest of Middle East Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 307: Rest of Middle East 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
TABLE 308: Rest of Middle East Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 309: Rest of Middle East Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 310: Rest of Middle East 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
TABLE 311: Rest of Middle East Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 312: Rest of Middle East Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 313: Rest of Middle East 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
AFRICA
Comprehensive Metabolic Panel Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
TABLE 314: Africa Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 315: Africa Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 316: Africa 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
TABLE 317: Africa Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 318: Africa Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 319: Africa 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
TABLE 320: Africa Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 321: Africa Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 322: Africa 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030